Institutional variability in testing for actionable genetic alterations in patients with stage IIIB/C or IV non-small cell lung cancer: A real-world study from the German prospective, observational, multicenter CRISP registry (AIO-TRK-0315).

doi:10.1016/j.ejca.2026.116265

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Institutional variability in testing for actionable genetic alterations in patients with stage IIIB/C or IV non-small cell lung cancer: A real-world study from the German prospective, observational, multicenter CRISP registry (AIO-TRK-0315).

European journal of cancer (Oxford, England : 1990) - 11 Mar 2026

Althoff Friederike C, Hummel Horst-Dieter, Kokowski Konrad, Elender Corinna, Grah Christian, Zacharias Stefan, Fleitz Annette, Jänicke Martina, Groth Annika, Ludwig Paula, Nusch Arnd, Reiser Marcel, Pelz Henning, Wiegand Jörg, Griesinger Frank, Thomas Michael, Eberhardt Wilfried E E, Sebastian Martin

Abstract excerpt

BACKGROUND: Molecular testing in NSCLC is essential for treatment selection, yet routine implementation remains inconsistent across institutions. Clinical evidence suggests that variability in testing may not be explained by patient or tumor characteristics but might be driven by institutional factors, potentially leading to adverse outcomes. We examined the extent to which variability in AGA testing is...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aged, 80 and over

Share to Carcinoma, Non-Small-Cell Lung

Share to Genetic Testing

Share to Germany

Share to Lung Neoplasms

Share to Neoplasm Staging

Share to Registries

Source

Open in PubMed

Identifiers

PMID: 41633313
DOI: 10.1016/j.ejca.2026.116265

Genes

AGA
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Institutional variability in testing for actionable genetic alterations in patients with stage IIIB/C or IV non-small cell lung cancer: A real-world study from the German prospective, observational, multicenter CRISP registry (AIO-TRK-0315).PMID 41633313Read ↗

Real-world EGFR testing practices for non-small-cell lung cancer by thoracic pathology laboratories across Europe.Semantic proximity Read ↗

Real-World Biomarker Test Ordering Practices in Non–Small Cell Lung Cancer: Interphysician Variation and Association With Clinical OutcomesSemantic proximity Read ↗

Real-World Biomarker Testing Patterns in Patients With Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) in a US Community-Based Oncology Practice Setting.Semantic proximity Read ↗

Genetic variant interpretation in tumours in the French national ring trials Gen&Tiss - main criteria of improvement.Semantic proximity Read ↗

Implementation Challenges and Disparities in Molecular Testing for Patients With Stage IV NSCLC: Perspectives from an Urban Safety-Net Hospital.Semantic proximity Read ↗

Variations in Genomic Testing in Non-small Cell Lung Carcinoma: A Healthcare Professional Survey of Current Practices in the UK.Semantic proximity Read ↗

Retrospective Comparison of Operational Metrics Across Diagnostic Approaches for Molecular Testing in Lung and Colon Cancers in a Community-Based Setting.Semantic proximity Read ↗

Temporal trends and regional variability in BRAF and KRAS genetic testing in Denmark (2010-2022): Implications for precision medicine.Semantic proximity Read ↗

Underutilization and disparities in access to EGFR testing among Medicare patients with lung cancer from 2010 - 2013.Semantic proximity Read ↗

Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer in the Real-World Setting in Central Europe: The INSIGHT Study.Semantic proximity Read ↗

EGFR mutation testing and TKI treatment patterns among veterans with stage III and IV non-small cell lung cancer.Semantic proximity Read ↗

Improving biomarker testing in advanced non-small-cell lung cancer and metastatic colorectal cancer: experience from a large community oncology network in the USA.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.